Pharming the Field: A Look at the Benefits and Risks of Bioengineering Plants to Produce Pharmaceuticals

Report Read time:
Pharming the Field: A Look at the Benefits and Risks of Bioengineering Plants to Produce Pharmaceuticals

The power of biotechnology now allows scientists to use plants as “factories” to produce a wide range of new products. One of the most exciting developments is the ability to use plants to produce human pharmaceuticals useful in treating cancer, cardiovascular disease, infectious diseases and other conditions. Developers hope this technology will lead to safer, more abundant and more affordable new medicines.

This powerful new application of biotechnology also raises questions about whether plantmade pharmaceuticals pose risks to humans and the environment, particularly if they are produced in plants that also serve as food or feed crops.

To shed light on these issues, the Pew Initiative on Food and Biotechnology, the U. S. Food and Drug Administration, and the Cooperative State Research, Education and Extension Service of the U. S. Department of Agriculture co-sponsored a two-day conference entitled Pharming the Field. This event brought together a broad range of interested parties to share information and exchange views on the potential benefits and risks associated with plant-made pharmaceuticals and to review the current laws and regulatory policies that apply to these plants.

The views that emerged from the conference are captured here to demonstrate the broad diversity of perspectives and to provide context for future dialogue on this very important issue. It should be noted that the exchanges among participants reflect only their opinions and not necessarily those of the sponsoring organizations.

Downloads Report Pharming the Field A Look at the Benefits and Risks of Bioengineering Plants to Produce Pharmaceuticals
Downloads Report Pharming the Field A Look at the Benefits and Risks of Bioengineering Plants to Produce Pharmaceuticals
America’s Overdose Crisis
America’s Overdose Crisis

America’s Overdose Crisis

Sign up for our five-email course explaining the overdose crisis in America, the state of treatment access, and ways to improve care

Sign up
Quick View
America’s Overdose Crisis

America’s Overdose Crisis

Sign up for our five-email course explaining the overdose crisis in America, the state of treatment access, and ways to improve care

Sign up

MORE FROM PEW

About a dozen people stand examining large blue bins full of whole fish in a warehouse. Some people are in green clothes, others in blue, and all wear ballcaps. A few hold clipboards. Reducing Risk Strengthens the Seafood Supply Chain
A worker in a seafood market dumps bright orange shrimp from a blue bin onto a bed of ice between a lot of other seafood laid out for sale. Other workers are visible in the background, as are the arms of shoppers placing orders from the other side of the ice bed. Seafood Industry Benefits From Greater Vessel Transparency
An aerial view of a vast wetland, with scattered vegetation visible on sandy islands. In Western Australia, a Conservation Model for the World
A presentation being given by a businesswoman to a group of participants at a business conference. Four Plan Features Can Boost 'Retirement Readiness'
Composite image of modern city network communication concept

Learn the Basics of Broadband from Our Limited Series

Sign up for our four-week email course on Broadband Basics
Quick View

How does broadband internet reach our homes, phones, and tablets? What kind of infrastructure connects us all together? What are the major barriers to broadband access for American communities?

Pills illustration
Pills illustration

What Is Antibiotic Resistance—and How Can We Fight It?

Sign up for our four-week email series The Race Against Resistance.
Quick View
Pills illustration

Antibiotic-resistant bacteria, also known as “superbugs,” are a major threat to modern medicine. But how does resistance work, and what can we do to slow the spread? Read personal stories, expert accounts, and more for the answers to those questions in our four-week email series: Slowing Superbugs.